Universal Ibogaine Provides Bi-weekly Default Status Report on 2025 Year-end Filings and Update on Restructuring Process

Universal Ibogaine (TSXV:IBO) has missed its November 28, 2025 deadline to file audited financial statements for the year ended July 31, 2025 and was granted a management cease trade order by the Alberta Securities Commission on December 4, 2025, triggering bi‑weekly default status reports. The company has temporarily closed its Kelburn Recovery Centre, is negotiating a Letter of Intent for a potential sale of the property to fund operations and complete the audit, and says the audit and filing may depend on the outcome of its restructuring and related TSXV approvals; it intends to resume focus on a planned Health Canada clinical trial application for ibogaine after restructuring. These developments materially increase execution and regulatory risk for shareholders while creating potential asset-sale proceeds and a path to resume filings and clinical programs if approvals and financing are obtained.

Analysis

Market structure: The MCTO, delayed audit and temporary clinic closure make IBOGF an idiosyncratic loser while acquirers of behavioral-health real estate and cash-rich biotech sponsors are the likely winners if a sale closes. Competitive dynamics shift away from operating addiction clinics (immediate loss of revenue) toward preserving IP and clinical-stage assets; pricing power for UI equity is essentially zero until audited statements and LOI terms are disclosed. Cross-asset effects are local: expect increased equity volatility and illiquidity in IBOGF, negligible impact on corporate credit markets, slight CAD microcap sentiment weakness, and no meaningful commodity or FX moves.

Risk assessment: Tail risks include TSXV delisting, Health Canada rejecting a CTA, or a fire-sale of Kelburn that leaves no runway—each could wipe equity value (>90% downside). Immediate window (days) has trading volatility and insider lock-ups under MCTO; short-term (4–12 weeks) hinges on LOI completion and audit filing; long-term (6–24 months) depends on CTA acceptance and licensing upside (low probability). Hidden dependencies: creditors’ claims and regulatory approval timing will determine whether sale proceeds fund the audit or instead trigger creditor enforcement; a single negative audit disclosure could accelerate insolvency.

Trade implications: Primary direct play is a tactical short/put exposure to IBOGF sized conservatively (1–3% NAV) given low liquidity; add if audit not filed within 8 weeks or LOI contains <6–12 months runway. Pair trade: short IBOGF vs long biotech ETF XBI (dollar neutral) to isolate idiosyncratic risk; options trade: buy 3-month ATM put spread (buy ATM, sell 25% OTM) to cap premium. Sector rotation: reduce microcap psychedelic/addiction exposures by ~25% and reallocate to larger-cap biotech ETF IBB for 3–6 months.

Contrarian angle: The market is likely over-penalizing potential upside if the LOI produces >12 months runway and management retains IP — history shows small biotechs can re-rate 3x+ post-clean audit and funded CTA, albeit rare. This is a binary event trade: if audited filings + LOI arrive within 6–12 weeks with verified cash runway, flip to a small conditional long (2–3% NAV) with tight 50% stop. Beware dilution risk and that upside requires successful regulatory milestones well beyond the near-term restructuring.

Key Decisions for Investors

• Establish a tactical short (or buy 3-month ATM put spread if options exist) sized 1–3% of portfolio NAV on IBOGF immediately; increase to 3–5% if audited financials are not filed within 8 weeks or LOI terms are not disclosed within 6 weeks. Target: 50–80% downside within 3 months; cover on audited filing that confirms ≥12 months runway.
• Initiate a dollar-neutral pair trade: short IBOGF vs long XBI (equal dollar) sized 1–2% NAV each to capture idiosyncratic downside while remaining sector-exposed; reassess at LOI/audit milestones (close pair or widen short if disclosures negative).
• Conditional event long: only establish 2–3% long position in IBOGF after (a) audited FY2025 filed and (b) LOI confirms sale proceeds sufficient for 12–18 month runway; set a hard stop-loss at 50% and target 3x return over 12–24 months contingent on CTA submission.
• Reallocate 20–30% of microcap psychedelic/addiction exposure into IBB over the next 2–6 weeks to reduce idiosyncratic restructuring risk and maintain biotech sector upside while avoiding single-name bankruptcy risk.